in first blood sample withdrawn after a minimum twelve-hour fast in 8 patients with proven insulinomas. Both techniques were not used on every specimen. Horizontal lines indicate the generally accepted upper limit for hypoglyccemia by each method (40 mg/100 ml glucose oxidase: 50 mg/100 ml non-specific reducing).
Twenty-one of 27 samples analysed (78 %/) .for glucose by glucose oxidase, and 10 of 24 (42 Y.<) by non-specific reducing methods showed hypoglyca-mia levels. Williams (1959) has stated that the normal EEG which may occur with chronic hypoglycwmia can become abnormal when normoglycamia is restored.
The low blood sugar level may not be the sole cause of cerebral dysfunction. The nearly or completely normal EEG which may occur with hypoglyceemia alone, can be converted to an abnormal one by the simple manceuvre of altering the blood pH by overbreathing. Reversion to normal occurs when overbreathing is discontinued or the hypoglyczmia corrected. Fraser et al. (1938) suggested that insulin mnight be toxic, especially in the presence of a low tissue glucose concentration. Support for this comes from the observations by Heller & Hesse (1960) that the respiration of isolated sciatic nerve is depressed when insulin is given to the intact animal. It is enhanced by insulin in vitro. This raises the possibility that degraded or altered, but not native insulin, impairs neural function. We have observed that glucagon and tolbutamide predispose to neuroglycopenia in the presence of a low blood glucose level.
The diagnosis of hyperinsulinism requires the demonstration of fasting hypoglycwmia the various causes of which are discussed by Howard (1955) and Conn &Seltzer (1955) .
Hypoglycwmia is an indication that glucose has been removed from the blood faster than it has been replenished. It has been shown that in hyperinsulinism the rate of glucose disappearance from the blood is usually normal though sometimes it is either increased or decreased . It is suggested that in most cases hypoglycemia from hyperinsulinism is due to the impaired release of glucose by the liver. Oral and intravenous glucose tolerance tests designed to measure the peripheral glucose uptake are of little value in the diagnosis of hyperinsulinism, and may be frankly misleading.
Fasting hypoglycemia is not always easily demonstrated though it is facilitated by using a glucose oxidase method for glucose analysis ( Fig  1) and also by activity, which increases peripheral glucose uptake. Provocative tests are valuable aids to diagnosis; though none is specific or absolute we have found the glucagon and tolbutamide tests particularly useful and the results of these are discussed in the next paper.
Glucagon and Tolbutamide Tests in the Recognition of Insulinomas by David Marrack MD, F Clifford Rose MB MRCP and Vincent Marks BM MRCPEd (London) In the preceding paper we pointed out some of the problems of correlating the symptoms and signs of neuroglycopenia with blood glucose concentrations in patients with hyperinsulinism. These problems complicate the diagnosis of insulinoma which depends upon the recognition of hypoglycaemia.
Although fasting for up to forty-eight hours with periods of exercise reveals most cases, never-theless a simple and reliable screening procedure is needed, which will provoke attacks at convenient times of the day in the quite numerous patients who have symptoms and signs which might be due to an insulinoma. The effects of glucagon (Marks 1960 ) and tolbutamide (Gittler et al. 1958 , Fajans & Conn 1959 , Fajans et al. 1961 ) on blood glucose concentration and the development of neuroglycopenia have been studied in cases of insulinoma and appear to fulfil this requirement. In our tests the blood glucose was estimated by a specific glucose oxidase method (Marks 1959) .
Glucagon Test
In the first 4 patients with insulinoma, previously reported by Marks (1960) , intramuscular glucagon precipitated neuroglycopenia in association with an abnormally low blood glucose concentration. This pattern of response has been seen neither in normal subjects nor in patients who were believed not to have insulinomas. It is, however, recorded in idiopathic hypoglycemia of infancy (Kinsbourne & Woolf 1959 , Cochrane et al. 1956 ).
The observations have been extended using the same method and our results in 33 control subjects and in 10 patients with insulinomas are shown in Fig 1. The two features of importance seem to be: (1) A normal rise in the blood glucose (2) A fall in blood glucose to levels less than 45 mg% at or before 180 minutes, with little, if any, rise subsequently.
Some patients with liver disease may not show the normally expected rise in blood glucose concentration and 2 such patients shown in Fig 2 had suffered spontaneous attacks of hypoglycemia.
Six out of ten patients with insulinomas had low fasting blood glucose concentrations before starting the test but only 1 had symptoms at this time; these disappeared as the blood glucose level rose during the test and reappeared as it fell. In 3 cases the test had to be stopped because severe symptoms of neuroglycopenia developed. The mean rise in blood glucose in the 10 patients was similar to that in the control group. In contrast to the control group all the patients with insulinoma developed hypoglycemia within one and a half to three hours after the injection of glucagon, though neuroglycopenia was not always apparent.
Two patients with reactive hypoglycemia were studied and the response was normal, confirming the findings of Alivisatos & McCullagh (1955) . This test seems to us to be valuable in screening patients for insulinomas as well as in differentiating the causes of spontaneous hypoglycemia.
It is of interest that the hypoglycemia induced by this test in patients with insulinoma responds to a further dose of glucagon as shown in Fig 3. The hyperglycemia following intramuscular adrenaline and intravenous glucose in these patients does not appear to have the sameeffect in provoking hypoglycemia as glucagon. The change in glucose concentration against time, after the peak (Wincey & Marks 1961) and is shown in the lower half of the diagram. The results are expressed graphically in the upper half and show the glycamic response to a second dose of glucagon during the hypoglyceamia produced by thefirst of the glucagon-induced hyperglycemia, closely approximates to a first order reaction and the glucose assimilation coefficient (G.A.C.) (Conard et al. 1953 was, in 4 of the cases, greater than that normally obtained with the intravenous glucose tolerance. The G.A.C.s in these 4 cases were similar to those we have obtained by giving insulin with glucose intravenously to control subjects. The significance of this observation is not clear.
Tolbutamide Test
In the tolbutamide test 1 gram of sodium tolbutamide dissolved in 15-20 ml of distilled water is given intravenously and the extent of the fall and the subsequent restitution of glucose concentration in capillary blood is followed for the next three hours. The mean response in 39 control subjects is shown in Fig 4, together with the data from 4 cases of insulinoma. The feature of these cases is the failure of the blood glucose to rise again after the initial fall, i.e. the response to hypoglycemia is disordered. In normal subjects the blood glucose always returns to at least 70% and usually 80°/ of the fasting level at three hours.
The findings with this test in various groups of patients in addition to those with insulinoma are shown in Fig 5. The pre-test blood glucose concentrationis plotted againstthepercentage drop in Fig 4 The mean blood glucose response ±2x S.D. expressed as a percentage of the fasting level, in 39 control subjects given 1 gram sodium tolbutamide intravenously at zero time is shown by the shaded area. The responses in 4 patients with insulinoma, not hypoglycawmic at the start ofthe test, are also shown glucose level at 90 minutes after the tolbutamide injection. On such a diagram (Fig 5) Seven tests in 6 -patients with insulinomas are shown. An additional test in 1 of these patients precipitated acute neuroglycopenia, progressing to coma in 26 minutes and is not shown in Fig 5. Patients who have given false positive tests include 2 patients with liver disease, 2 probable cases of pluriglandular syndrome, and a patient with a pituitary tumour.
In 3 of the patients with insulinoma there was little change ir the blood glucose concentration during the test yet severe neuroglycopenia developed in 2, and mild neuroglycopenia in 1. The EEG was abnormal in the patient examined.
One of the diagnostic difficulties with insulinoma is that the tumour usually grows slowly-and the symptoms are progressive. The advanced case which may already have severe neural damage is easily recognized by a period of fasting which causes hypoglycwmia. But even in these cases the fast may need to be continued for as long as fortyeight to seventy-two hours. The detection of early cases, before there is neuronal disorganization, is more difficult. The above tests seem to offer a partial solution to this problem and have the advantage that in doubtful cases they can be repeated after a suitable time interval.
The glucagon and tolbutamide tests appear to test two different aspects of glucose homeostasis and we believe that they have a useful role to play in the screening of patients suspected of insulinoma.
A New Oral Progestogen in the Treatment of Dysmenorrh(ea by P M F Bishop DM FRCP (London) An entirely new series of steroid compounds has been recently synthesized by Reerink and his colleagues in which the stereochemical configuration has been altered by reversing the spatial position of the substituents at C9 and C10 (Reerink et al. 1960) . In progesterone the angle methyl group at C10 is in the P (or cis) position whereas the hydrogen atom attached to Cg is in the oc (or trans) position ( Fig IA) .
The corresponding compound (retro-progesterone) in the new series is the 9fl, 10ac stereoisomeric analogue (Fig 1B) .
The 6-dehydro-derivative has been found by Scholer (1960) to be a pure progestational compound with no cestrogenic or androgenic properties. It has been given the trivial name of isopregnenone and is shortly to be marketed under the trade name of Duphaston (Fig ic) .
A study of the human pharmacological properties of isopregnenone as a progestational agent was carried out in the Department of Women's Diseases of the Karolinska Sjukhuset in Stockholm by Dr Egon Diczfalusy and Dr Tillinger, in the Department of Obstetrics and Gyn=cology of the University of Gdteborg by Professor Ulf Borell and in my Department at Chelsea Hospital for Women. It was shown that this compound induced classical progestational transformation of the cestrogen-primed endometrium in castrated women and in cases of primary and long-standing secondary amenorrhoea. The results of these human pharmacological studies will be published in due course (Bishop et al. 1961 ). The present communication concerns the effect of isopregnenone in dysmenorrhoea.
We have selected for our trials only patients complaining of 'incapacitating' dysmenorrhoea, that is pain sufficiently severe to keep them in bed, absent from school or away from work and occurring in practically every cycle. At least 75% of these patients had received previous treatment such as dilatation of the cervix, antispasmodics, analgesics or sedatives without appreciable effect.
In 1940 Sturgis & Albright suggested that spasmodic dysmenorrhoea was due to the presence of endogenous progesterone and could be prevented in any menstrual cycle by inhibiting ovulation. For many years this has been successfully achieved by suppressing pituitary gonadotrophin release with cestrogens administered in the first half of the cycle (Bishop & Orti 1952) . Pincus and his colleagues (1958) showed that orally active progestational agents, such as norethynodrel, can inhibit ovulation and therefore act as contraceptives, by
